Volume 30, Number 9—September 2024
Dispatch
Epidemiology of Lyme Disease Diagnoses among Older Adults, United States, 2016–20191
Table
Characteristics of Lyme disease diagnoses according to Medicare fee-for-service claims data versus cases identified by national surveillance in a population of persons > 65 years of age, United States, 2016–2019*
Characteristic | High-incidence states |
Neighboring states |
Low-incidence states |
|||||
---|---|---|---|---|---|---|---|---|
Medicare | Surveillance | Medicare | Surveillance | Medicare | Surveillance | |||
Person-years | 72,298 | NA | 5,958 | NA | 10,009 | NA | ||
Diagnoses or cases, no. | 72,455 | 31,879 | 5,978 | 1,714 | 10,052 | 590 | ||
Diagnoses or cases, % | 81.9 | 93.3 | 6.7 | 5.0 | 11.3 | 1.7 | ||
Incidence among men | 422.9 | 71.0 | 38.3 | 4.6 | 30.1 | 0.6 | ||
Incidence among women | 321.3 | 46.6 | 33.4 | 3.0 | 29.2 | 0.5 | ||
Occurring in May–August, % | 59.5 | 72.2 | 58.2 | 79.9 | 45.8 | 66.2 | ||
Median incidence, 2016–2019 (range) | 346.9 (337.2–417.8) |
57.1 (52.9–65.6) | 35.3 (27.9–36.6) | 3.6 (2.4–5.3) | 29.4 (27.7–31.6) |
0.6 (0.5–0.6) |
*Incidence calculated as diagnoses/100,000 person-years in Medicare fee-for-service or cases/100,000 population among each surveillance subcategory. NA, not applicable.
1Preliminary results from this study were presented at the International Conference on Emerging Infectious Diseases; August 7–10, 2022, Atlanta, Georgia, USA.